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Introduction 
The cutaneous microbiome is a diverse microbial 
community that plays a critical role in the innate and 
adaptive immune responses and maintenance of 
skin barrier function [1, 2]. The hygiene hypothesis 
proposes that a lack of early childhood pathogen 
exposure related to over-cleansing and antimicrobial 
use limits natural immune development, including 
that of the skin barrier, and predisposes one to 
develop allergic conditions [3-5]. Additionally, 
cutaneous dysbiosis alters the immune milieu and 
has been implicated in a number of skin diseases, 
including atopic dermatitis (AD), psoriasis, acne 
vulgaris, and seborrheic dermatitis [1, 6]. In the past 
decade, commercially available topical probiotics 
have gained tremendous popularity — a Google 
search of “topical probiotics” yields over 3 million 
results. Despite their rising popularity amongst the 
general public, how much information is the medical 
community equipped with regarding the safety and 
efficacy of topical probiotics? 
 
Discussion 
In contrast to topical bacteriotherapy, the transplant 
of skin microbiota from one person to another, 
topical probiotics involve the transfer of laboratory-
cultured bacteria. Use of topical bacteriotherapy was 
first proposed as a treatment for cutaneous diseases 
in 1912, when topical application of Lactobacillus 
bulgaricus was reported to improve acne and 
seborrhea [7]. Following the boom of oral probiotics,  
Abstract 
Objective: Topical probiotics have been used for skin 
care and treatment since the early 20th century. Over 
the past decade, there has been a dramatic surge of 
commercially-available topical probiotic products. 
We conducted a systematic search of clinical data 
relating to the use of topical probiotics and identified 
relevant clinical and regulatory gaps. 
Methods: PubMed and Google Scholar searches 
were conducted for trials and reviews of probiotics. 
FDA definitions of cosmetics, drugs, and regulation of 
topical probiotics were reviewed. 
Results: Topical probiotics have shown efficacy in a 
number of limited trials, particularly those involving 
the treatment of acne, atopic dermatitis, and rosacea. 
However, there is a paucity of literature on the safety 
profiles, mechanistic action, and therapeutic 
potential of topical probiotic products. Several 
regulatory gaps exist, including approval and 
classification of topical probiotic products by the 
FDA; currently there are no topical probiotic products 
the FDA has approved as drugs. 
Conclusion: With increasing popularity among the 
general public, but insufficient clinical data to 
demonstrate large-scale effectiveness and a 
thorough understanding of side effects, there is a 
need for further mechanistic and clinical 
investigation, as well as improved regulation and 
standardization of topical probiotic products. 
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numerous topical probiotic formulations have been 
proposed to correct skin dysbiosis and establish 
immune homeostasis by equilibrating the skin 
microbiota [3]. Topical probiotics have 
demonstrated notable efficacy in limited clinical 
trials in acne, atopic dermatitis, and rosacea [8-13]. 
Although the exact mechanism of probiotics remains 
unknown, they are hypothesized to exert anti-
inflammatory effects by stimulating regulatory T-
cells and release of anti-inflammatory cytokines such 
as IL-10, competing with pathogens for nutrients and 
aggregating and displacing pathogens [14]. 
Probiotic strains containing commensal skin 
microbes such as Lactobacillus, Bifidobacterium, or 
Streptococcus have demonstrated cutaneous 
immuno-regulatory effects through inhibition of 
biofilm formation, reduction of systemic 
inflammatory cytokines, and direct, competitive 
inhibition of binding sites [6, 7]. Lactobacilli 
specifically exhibit antimicrobial activity against skin 
pathogens including Escherichia coli, Pseudomonas 
aeruginosa, and pathobionts (resident microbes with 
pathogenic potential), such as Cutibacterium 
(formerly Propionibacterium) acnes [6]. Recently, a 
small open label study of 10 adults and 5 pediatric 
AD patients treated with topical microbiome 
transplantation (Roseomonas mucosa lysate cultured 
from healthy volunteers) led to a >50% 
improvement in SCORing Atopic Dermatitis 
(SCORAD) index in 10 patients (P=0.016). R. mucosa is 
believed to improve AD symptoms by restoring 
epithelial barrier function and innate/adaptive 
immune balance as well as via inhibition of S. aureus 
growth [15]. 
Despite promising findings in preliminary 
bacteriotherapy studies, the mechanism and side 
effects of topical probiotics remain largely unknown. 
Transfer of antibiotic resistance among pathogens, 
bacteremia, and allergic reactions to inactive 
ingredients have been proposed as potential 
adverse effects. However, a recent review by the 
Agency for Healthcare Research and Quality (AHRQ) 
concluded that the available literature is not 
sufficiently equipped to determine the safety of 
probiotic use with confidence [16]. Furthermore, the 
clinical effects of topical probiotics also vary 
depending on bacterial speciation. A 2017 study of 
14 topical probiotic species found that each species 
had a unique spectrum of characteristics, including 
keratin adhesion, inhibitory action, organic acid 
production, and inhibition of biofilm formation [6]. 
The isolation of probiotics from their natural 
environments inhibits quorum sensing and may 
produce behavior distinct from that exhibited in 
their native microbial communities. 
Currently, the FDA categorizes probiotics into 
different product categories such as foods, food 
additives, cosmetics, dietary supplements, medical 
devices, or drugs on a case-by-case basis, but does 
not have a regulatory definition or agency that 
specifically addresses topical probiotics [17]. At this 
time, there are no probiotics approved as drugs by 
the FDA [17]. Although topical probiotic products are 
used to mitigate skin pathologies, their utilization 
applies more towards the product category of 
“cosmetics,” which the FDA defines as products used 
to cleanse or beautify the body [17]. The FDA does 
not require cosmetic products and ingredients to 
have FDA approval prior to marketing [18]. 
Therefore, probiotic labeling by manufacturers may 
include unsubstantiated therapeutic claims, and 
consumer use in pursuit of these unproven benefits 
is a growing concern. 
Future investigations should evaluate the efficacy 
and safety of topical probiotics, as the need for 
improved regulations and labeling will be an 
ongoing dialogue. Should probiotics and 
bacteriotherapy become approved as 
biotherapeutics, these investigations will pave the 
way for more appropriate regulation and 
standardization of effective clinical use. Additionally, 
further investigations in dermatologic conditions for 
which probiotics have demonstrated efficacy (AD, 
acne, rosacea) will help to elucidate the mechanisms 
by which probiotics are able to ameliorate disease 
symptoms. 
 
Conclusion 
Although emerging evidence holds promise, the 
current view of topical probiotics among 
dermatologists is one of excitement and cautious 
optimism. Further investigations are needed to more  
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thoroughly evaluate their benefits and safety. 
Additional efforts by the FDA to better define topical 
bacteriotherapy will help to establish guidelines for 
product safety and intended use. Patients seeking 
information about the use of over-the-counter 
topical probiotics should be advised about their 
potential clinical benefits but should also be 
informed of the remaining unknowns regarding their 
mechanism of action and potential adverse effects. 
Larger scale clinical trials evaluating efficacy and 
further research into the mechanisms of topical  
probiotic formulations should be undertaken to 
broaden our understanding of their potential 
therapeutic applications. Topical probiotics are a 
promising therapeutic option for inflammatory 
cutaneous pathologies and future clinical trials and 
reports regarding their efficacy will be eagerly 
awaited. 
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